D. Hamish Wright

416 total citations
15 papers, 344 citations indexed

About

D. Hamish Wright is a scholar working on Pharmacology, Immunology and Molecular Biology. According to data from OpenAlex, D. Hamish Wright has authored 15 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in D. Hamish Wright's work include Inflammatory mediators and NSAID effects (4 papers), Hepatitis C virus research (3 papers) and Nitric Oxide and Endothelin Effects (2 papers). D. Hamish Wright is often cited by papers focused on Inflammatory mediators and NSAID effects (4 papers), Hepatitis C virus research (3 papers) and Nitric Oxide and Endothelin Effects (2 papers). D. Hamish Wright collaborates with scholars based in United States, Canada and Belgium. D. Hamish Wright's co-authors include Kathleen M. Metters, Anthony W. Ford‐Hutchinson, F. Nantel, Mark Abramovitz, Kris Chadee, Martin Desrosiers, Gary P. O’Neill, Sonia Lamontagne, François G. Gervais and Adel Giaid and has published in prestigious journals such as Blood, Journal of Hepatology and British Journal of Pharmacology.

In The Last Decade

D. Hamish Wright

14 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Hamish Wright United States 8 144 120 103 56 45 15 344
Alysia Kern Lovgren United States 6 186 1.3× 69 0.6× 171 1.7× 53 0.9× 69 1.5× 6 501
A. Nakao Japan 12 87 0.6× 79 0.7× 180 1.7× 53 0.9× 35 0.8× 20 455
Petra Luschnig Austria 9 93 0.6× 134 1.1× 95 0.9× 30 0.5× 16 0.4× 12 379
W Uracz Poland 14 60 0.4× 101 0.8× 104 1.0× 60 1.1× 26 0.6× 40 529
Dae‐Seog Heo South Korea 11 114 0.8× 38 0.3× 81 0.8× 34 0.6× 43 1.0× 22 371
F Russo-Marie France 9 70 0.5× 89 0.7× 198 1.9× 43 0.8× 69 1.5× 24 454
Naritoshi Shirata Japan 10 55 0.4× 81 0.7× 135 1.3× 34 0.6× 25 0.6× 11 332
Catherine Borg United Kingdom 8 54 0.4× 88 0.7× 130 1.3× 27 0.5× 19 0.4× 17 272
Emmanuel Coroneos United States 7 64 0.4× 79 0.7× 236 2.3× 39 0.7× 26 0.6× 8 390
D. Staumont France 6 331 2.3× 129 1.1× 61 0.6× 31 0.6× 35 0.8× 15 583

Countries citing papers authored by D. Hamish Wright

Since Specialization
Citations

This map shows the geographic impact of D. Hamish Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Hamish Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Hamish Wright more than expected).

Fields of papers citing papers by D. Hamish Wright

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Hamish Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Hamish Wright. The network helps show where D. Hamish Wright may publish in the future.

Co-authorship network of co-authors of D. Hamish Wright

This figure shows the co-authorship network connecting the top 25 collaborators of D. Hamish Wright. A scholar is included among the top collaborators of D. Hamish Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Hamish Wright. D. Hamish Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
DiNardo, Courtney D., Stephen A. Strickland, Barry Skikne, et al.. (2023). A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood. 142(Supplement 1). 1548–1548. 1 indexed citations
2.
Olszewski, Adam J., David Kahn, Byong Kwon Yoo, et al.. (2023). A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies. Blood. 142(Supplement 1). 3102–3102. 3 indexed citations
3.
Wu, Yin, Min Ye, Evan Paull, et al.. (2023). Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile. Blood. 142(Supplement 1). 2997–2997. 2 indexed citations
4.
Caro, Luzelena, Jan de Hoon, Caroline Cilissen, et al.. (2017). Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men. Clinical and Translational Science. 10(6). 480–486.
5.
Wright, D. Hamish, Kevin Brown, Geng‐Chang Yeh, et al.. (2015). Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay. Current Therapeutic Research. 77. 116–121. 1 indexed citations
6.
Wright, D. Hamish, Michael Cerra, Lihong Du, et al.. (2014). Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients. Antiviral Therapy. 20(8). 843–848. 11 indexed citations
7.
Asselah, Tarik, E Zehnter, Krishna Mohan Agarwal, et al.. (2014). P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE. Journal of Hepatology. 60(1). S458–S459. 2 indexed citations
8.
Wright, D. Hamish, Julie A. Stone, Larissa Wenning, et al.. (2013). Pharmacokinetic–pharmacodynamic studies of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor MK‐0916 in healthy subjects. British Journal of Clinical Pharmacology. 76(6). 917–931. 17 indexed citations
9.
Wright, D. Hamish, et al.. (2009). Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin. The Journal of Clinical Pharmacology. 49(10). 1157–1167. 17 indexed citations
10.
Nantel, F., Sonia Lamontagne, D. Hamish Wright, et al.. (2004). Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins & Other Lipid Mediators. 73(1-2). 87–101. 64 indexed citations
11.
Wright, D. Hamish, Daniel Abran, Mousumi Bhattacharya, et al.. (2001). Prostanoid receptors: ontogeny and implications in vascular physiology. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 281(5). R1343–R1360. 68 indexed citations
12.
Wright, D. Hamish, Anthony W. Ford‐Hutchinson, Kris Chadee, & Kathleen M. Metters. (2000). The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. British Journal of Pharmacology. 131(8). 1537–1545. 39 indexed citations
13.
Wright, D. Hamish, F. Nantel, Kathleen M. Metters, & Anthony W. Ford‐Hutchinson. (1999). A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. European Journal of Pharmacology. 377(1). 101–115. 52 indexed citations
14.
Wright, D. Hamish, Kathleen M. Metters, Mark Abramovitz, & Anthony W. Ford‐Hutchinson. (1998). Characterization of the recombinant human prostanoid DP receptor and identification of L‐644,698, a novel selective DP agonist. British Journal of Pharmacology. 123(7). 1317–1324. 65 indexed citations
15.
Smith, Graeme, D. Hamish Wright, J. A. Child, et al.. (1992). A pilot study of chlophepp‐B—A weekly regimen for patients with untreated advanced or recurrent hodgkin's disease. Hematological Oncology. 10(6). 311–318. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alysia Kern Lovgren Breakdown of academic impact, for papers by A. Nakao Breakdown of academic impact, for papers by Petra Luschnig Breakdown of academic impact, for papers by W Uracz Breakdown of academic impact, for papers by Dae‐Seog Heo Breakdown of academic impact, for papers by F Russo-Marie Breakdown of academic impact, for papers by Naritoshi Shirata Breakdown of academic impact, for papers by Catherine Borg Breakdown of academic impact, for papers by Emmanuel Coroneos Breakdown of academic impact, for papers by D. Staumont
Rankless by CCL
2026